A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
- Registration Number
- NCT00631943
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Lyrica in Indian patients with nerve pain
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 112
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Pregabalin (Lyrica) -
- Primary Outcome Measures
Name Time Method Change from baseline in weekly mean pain scores Weeks 1 and 2 and end of treatment Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) visual analog score (VAS) Weeks 1 and 2 and end of treatment
- Secondary Outcome Measures
Name Time Method Change from baseline in pain interference scores on the Brief Pain Inventory (BPI ) Short-Form End of treatment Change from baseline in sensory, affective, and total components of the pain descriptor score and the Present Pain Intensity (PPI) of the SF-MPQ Weeks 1 and 2 and end of treatment Change from baseline in Clinical Global Impression of Change (CGIC) Weeks 1 and 2 and end of treatment Change from baseline in Patient Global Impression of Change (PGIC) Weeks 1 and 2 and end of treatment Change from baseline in Euro Quality of Life Questionnaire (EQ-5D) scores End of treatment Adverse events and laboratory value changes Weeks 1 and 2 and end of treatment Change from baseline in weekly mean sleep interference score Weeks 1 and 2 and end of treatment
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇮🇳Chennai, Tamil, Nadu, India